Trade

with

Nektar Therapeutics Inc
(NASDAQ: NKTR)
AdChoices
13.25
+0.58
+4.58%
After Hours :
13.25
+0.00
+0.01%

Open

12.50

Previous Close

12.67

Volume (Avg)

1.17M (1.30M)

Day's Range

12.50-13.40

52Wk Range

8.87-15.34

Market Cap.

1.61B

Dividend Rate ( Yield )

-

Beta

1.47

Shares Outstanding

127.30M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 148.92M

    • Net Income

    • -162.01M

    • Market Cap.

    • 1.61B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -101.92

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.47

    • Forward P/E

    • -196.08

    • Price/Sales

    • 10.89

    • Price/Book Value

    • -45.66

    • Price/Cash flow

    • -40.65

      • EBITDA

      • -104.73M

      • Return on Capital %

      • -32.11

      • Return on Equity %

      • -

      • Return on Assets %

      • -32.11

      • Book Value/Share

      • -0.28

      • Shares Outstanding

      • 127.30M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 20.50

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -0.03

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -15.80

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 10.55

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 75.17

            • 82.75

            • Pre-Tax Margin

            • -100.35

            • 39.38

            • Net Profit Margin

            • -101.92

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 69.40

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -134.10

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -134.90

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 3.54

              • 2.92

              • Quick Ratio

              • 3.31

              • 2.35

              • Interest Coverage

              • -2.52

              • 38.02

              • Leverage Ratio

              • -

              • 2.21

              • Book Value/Share

              • -0.28

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -10.64

                • 277.78

                • P/E Ratio 5-Year High

                • -13.55

                • 634.30

                • P/E Ratio 5-Year Low

                • -3.43

                • 124.82

                • Price/Sales Ratio

                • 10.83

                • 9.35

                • Price/Book Value

                • -45.45

                • 8.50

                • Price/Cash Flow Ratio

                • -40.65

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -32.11

                    (-22.90)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 2.02

                  • 1.48

                  • Asset Turnover

                  • 0.32

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -120.13M
                  Operating Margin
                  -80.67
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -40.65
                  Ownership

                  Institutional Ownership

                  90.31%

                  Top 10 Institutions

                  61.99%

                  Mutual Fund Ownership

                  69.38%

                  Float

                  80.76%

                  5% / Insider Ownership

                  1.23%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Oppenheimer Global Opportunities

                  •  

                    24,000,000

                  • -1.64

                  • 18.85

                  • PrimeCap Odyssey Aggressive Growth Fund

                  •  

                    9,702,330

                  • 0.90

                  • 7.62

                  • Federated Kaufmann Fund

                  •  

                    4,610,000

                  • -7.80

                  • 3.62

                  • First Trust NYSE Arca Biotech Fund

                  •  

                    4,148,065

                  • 1.77

                  • 3.41

                  • PrimeCap Odyssey Growth Fund

                  •  

                    3,883,856

                  • 4.10

                  • 3.05

                  • Vanguard Explorer Fund

                  •  

                    2,478,300

                  • 0.00

                  • 1.95

                  • Vanguard US Opportunities

                  •  

                    2,218,100

                  • 0.79

                  • 1.74

                  • Vanguard Small Cap Index

                  •  

                    2,211,208

                  • -0.10

                  • 1.74

                  • Franklin Biotechnology Discovery

                  •  

                    2,113,300

                  • 54.96

                  • 1.66

                  • SPDR® S&P Pharmaceuticals ETF

                  •  

                    2,077,287

                  • 0.00

                  • 1.71

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • OppenheimerFunds, Inc.

                  •  

                    24,400,000

                  • 0.00%

                  • 19.17

                  • PRIMECAP Management Company

                  •  

                    15,804,286

                  • +1.74%

                  • 12.42

                  • Vanguard Group, Inc.

                  •  

                    8,080,240

                  • -0.82%

                  • 6.35

                  • Federated Global Inv Mgmt Corp

                  •  

                    5,910,834

                  • +788.85%

                  • 4.64

                  • First Trust Advisors L.P.

                  •  

                    5,256,759

                  • +17.87%

                  • 4.13

                  • State Street Corp

                  •  

                    4,681,405

                  • +11.64%

                  • 3.68

                  • BlackRock Fund Advisors

                  •  

                    4,480,672

                  • -7.87%

                  • 3.52

                  • J.P. Morgan Investment Management Inc.

                  •  

                    3,801,685

                  • -0.62%

                  • 2.99

                  • Granahan Investment Management Inc..

                  •  

                    3,442,980

                  • -6.30%

                  • 2.70

                  • Franklin Advisers, Inc.

                  •  

                    3,036,700

                  • -0.24%

                  • 2.39

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  Nektar Therapeutics, Inc., was incorporated in July 1990 and reincorporated in Delaware in 1998. The Company is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polym...moreer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its current proprietary pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. Its research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. The Company creates its drug candidates by using its proprietary advanced polymer conjugate technologies and expertise to modify the chemical structure of drugs to create new mole...morecular entities. The Company’s drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its proprietary drug candidate, NKTR-118, is an oral peripherally-acting opioid antagonist, currently in Phase 3 clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain and cancer pain. OIC is a common side effect of prescription opioids when used for chronic pain management. In September 2009, the Company entered into a global license agreement with AstraZeneca AB for the development and commercialization of NKTR-118 and NKTR-119. NKTR-119 is an early stage research and development program that is designed to combine various opioids with NKTR-118. AstraZeneca is responsible for all clinical, regulatory and commercialization costs for NKTR-118 and NKTR-119. The Company has several proprietary pre-clinical and clinical drug candidates that are in the pain therapeutic area. NKTR-181 is an orally-available mu-opioid analgesic molecule with a long-acting profile to treat chronic pain that has been designed with the objective of addressing serious CNS-related side effects associated with standard opioid therapies. The Company also has a collaboration with Bayer Healthcare LLC "Bayer" to develop BAY41-6551 (Amikacin Inhale, formerly known as NKTR-061), which is an inhaled solution of amikacin, an aminoglycoside antibiotic. Bayer has initiated a Phase 3 clinical development of BAY41-6551 with the first patient enrolled in April 2013. The Company frequently competes with pharmaceutical companies and other institutions. As a manufacturer of PEG reagents for the U.S. market, the Company is subject to inspections by the FDA for compliance with cGMP and other U.S. regulatory requirements, including U.S. federal, state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others. Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time.lessless

                  Key People

                  Mr. Howard W. Robin

                  CEO/Director/President

                  Mr. Robert B. Chess

                  Chairman of the Board/Director

                  John Nicholson

                  CFO/Senior VP

                  Ms. Jillian B. Thomsen

                  Chief Accounting Officer/Senior Executive VP, Divisional

                  Mr. Joseph J. Krivulka

                  Director

                  • Nektar Therapeutics Inc

                  • 455 Mission Bay Boulevard South

                  • San Francisco, CA 94158

                  • USA.Map

                  • Phone: +1 415 482-5300

                  • Fax: +1 415 339-5300

                  • nektar.com

                  Incorporated

                  1990

                  Employees

                  445

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: